Faculty Members

John Mackey

Medical Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta T6G 1Z2
Tel: 780.432.8221


I direct the Clinical Trial Unit at the Cross Cancer Institute, a highly motivated team of investigators and experience staff that enters nearly 15% of our patients on cancer therapy trials.  As the Co-Chair of Research for the Northern Alberta Breast Cancer Program, I supervise the clinical and research programs for women with breast cancer in the referral area of the Cross Cancer Institute, Edmonton. I am Executive Director of Translational Research in Oncology, a global network of academic investigators carrying out trials of novel anticancer drug treatments. As a medical oncology clinical investigator, my major interest is in the clinical testing of new biological, hormonal, and cytotoxic drugs for the treatment of early stage and advanced disease. I serve on the steering committees of eleven international systemic therapy trials.

Systemic therapy for breast cancer is frequently limited by drug resistance. My translational research program focuses on the study of the molecular mechanisms underlying drug resistance, and explores novel ways to circumvent and modulate these resistance mechanisms. With my collaborators, we are developing tests to predict which patients are most likely to benefit from anticancer therapy, and exploiting novel targets and pathways to improve systemic cancer therapy.
My research program is funded by the National Cancer Institute of Canada, the Alberta Cancer Board, the Alberta Cancer Foundation, the Alberta Chapter of the Canadian Breast Cancer Research Alliance, the Canadian Breast Cancer Research Alliance, the Department of Defense, and several industry sponsors.
Research Facilities and Affiliations
My primary academic appointment is in the Division of Medical Oncology in the Department of Oncology. I also hold a cross appointment in the Division of Experimental Oncology.



Primary Research articles in peer-reviewed journals (last 5 years only)
Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Olah A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Buchler MW; for the European Stufy Group for Pancreatic Cancer. Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. J Natl Cancer Inst. 2013 Dec 3.
Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure A, Seguí MA, Tredan O, Antón A, Ramos M, Del Carmen M, Rodríguez-Martín C, Carrasco E, Alba E. Obesity and Survival in Operable Breast Cancer Patients Treated with Adjuvant Anthracyclines and Taxanes According to Pathological Subtypes: A Pooled Analysis. Breast Cancer Res. 2013 Nov 6;15(6):R105.
Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Cook D, Jerpersen D, Proulx C, Dolan LB, Forbes CC, Wooding E, Trinh L, Segal RJ. Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Mulicenter Randomized Trial. J Natl Cancer Inst. 2013 Oct 22 [Epub ahead of print].
Cameron D, Brown J, Dent R, Jackisch C, Mackey JR, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Lae R, Im YJ, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant Bevacizumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of Randomized, Phase 3 Trial.  Lancet Oncol. 2013 Sep:14(10):933-42.
Tang Y, Mackey JR, Lai R, Ghosh S, Santos C, Graham K, Damaraju S, Pasdar M, Li L. Quantitative Proteomic Analysis of HER2 Normal and Overexpressing MCF-7 Breast Cancer Cells Revealed Proteomic Changes Accompanied with HER2 Gene Amplification. J Proteomics. 2013 Jul 11 in press.
North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass CE, Mackey JR. Expression of nucleoside transporters (NT) and deoxycytidine kinase (dCK) proteins in muscle invasive urothelial carcinoma of the bladder (UCCB): correlation with pathologic response to neoadjuvant platinum/gemcitabine combination chemotherapy (NAC). J Urol. 2013 Jul 10.
Au HJ, Eiermann W, Robert NJ, Pienkowshi T, Crown J, Martin M, Pawlicki M, Chan A, Mackey JR, Glapsy J, Pinter T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ; on behalf of the Translational Research In Oncology in Oncology BCIRG 006 trial investigators. Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab- Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer Results from the BCIRG 006 Study. Oncologist 2013 Jun 28.
Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S, Robson PJ, Kopciuk K, Cass CE, Yasui Y, Damaraju S.  Assessing SNP-SNP Interactions Among DNA Repair, Modification and Metabolism Related Pathway Gene Breast Cancer Susceptibility.  PLoS One.  2013 Jun 3; 8(6): E64896.
Sapkota Y, Yasui Y, Lai R, Sridharan M, Robson PJ, Cass CE, Mackey JR, Damaraju S. Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm. PLoS One. 2013 May 22;8(5):e62550.
Hajiloo M, Sapkota Y, Mackey JR, Robson P, Greiner R, Damaraju S. ETHNOPRED: A Novel Machine Learning Method for Accurate Continental and Sub-Continental Ancestry Identification and Population Stratification Correction. BMC Bioinformatics 2013 Feb 22; 14:61
Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y,  Mackey JR, Damaraju S. Gremline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence. PLos One. 2013;8(1):e53850. 2013 Jan 16.
Scott JM, Lakoski S, Mackey JR, Douglas PS, Haykowsky MJ, Jones LW. The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics. Oncologist. 2013 Jan 18.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Winholes J, Pinter T, Rodriguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; for the TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80
Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, Jones LW. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012 Dec 4;126(23):2749-63.
Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimizing therapeutic outcomes. Ann Oncol. 2012 Sep; 23(9): 2223-34.
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey JR, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15;18(12) :3478-86.
Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, Jones LW. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012 Dec 4; 126(23):2749-63.
Courneya KS, Vallance JK, Culos-Reed SN, McNeely ML, Bell GJ, Mackey JR, Yasui Y, Yuan Y, Matthews CE, Lau DC, Cook D, Friedenreich CM. The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. BMC Cancer. 2012 Nov 16; 12(1):525. [Epub ahead of print]
Koelwyn GJ, Khouri M, Mackey JR, Douglas PS, Jones LW.  Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship.  Journal of Clinical Oncology.  Oct 8, 2012 [Epub ahead of print].  PMID: 23045598. [PubMed – as supplied by publisher].
Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh S, Santos C, Mackey JR.  Prognostic Significance of Tissue Inhibitor of Metallproteinase-1 in Breast Cancer.  International Journal of Breast Cancer.  Volume 2012 (2012:290854) [Epub 2012 Sep 4]. PMID: 22988515.
Scott JM, Lakoski SG, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Mechanistic properties of aerobic exercise to modulate cardiotoxicity of targeted cancer therapeutics. Oncologist. In Press. 2012 Aug.
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012 Sep; 143(3):664-74.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey JR, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012 Apr 4;486(7403):395-9.
Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimizing therapeutic outcomes. Annals of Oncology 2012;
Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A, Pritchard KI. Controlling angiogenesis in breast cancer; A systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012 Oct;38(6):673-88.
Liu RZ, Graham K, Glubrecht DD, Lai R, Mackey  JR, Godbout R. A Fatty Acid-Binding Protein 7/RARβ Pathway Enhances Survival and Proliferation in Triple-Negative Breast Cancer. J Pathol. 2012 Nov;228(3):310-21
Sapkota Y, Robson P, Lai R, Cass CE, Mackey JR, Damaraju S. A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. European Journal of Human Genetics. 2012 Jan 1
Mason AL, Gilady SY, Mackey JR. Mouse mammary tumor virus in human breast cancer: red herring or smoking gun?  Am J Pathol. 2011 Oct;179(4):1588-1590. 
Eiermann  W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III Study of Doxorubicin/Cyclophosphamide with Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients with Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol. 2011 Sep 12. [Epub ahead of print].
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, MigliaccioI, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with Tamoxifen in patients with hormone receptor-positive metastatic breast cancer; a randomized Phase II study. Clin Cancer Res. 2011 Mar 1;17(5):1147-59.
Bachet JB, Marehal R, Mackey JR, Dalban C, Demetter P, Graham K, Couveland A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Andre T, Hannoun L, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF, Van Laethem JL. Valeur predictive de l’analyse combinee  de hENT1 et dCK pour le benefice de la gemcitabine en adjuvant après resection d’un adenocarcinoma du pancreas.  2011 Journees Francophones d’Hepato-gastroenterologie et d”Oncologie Digestive (JFHOD).
Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, Oudit G, Chow K, Pagano JJ, Paterson I. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANITCORE 101 – Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among women with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011 Jul 27;11(1):318.
Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Banos A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR.  Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Oncol. 2011 Apr;12(4):369-76.
Scott Jessica M, Khakoo Aarif, Mackey JR, Haykowsky Mark J, Douglas Pamela S, Jones Lee W. Modulation of Anthracycline-induced Cardiotoxicity by Aerobic Exercise in Breast Cancer: Current Evidence and Underlying Mechanisms. Circulation. 2011 Aug 2;124(5):642-50.
Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. Association  of FABP5 Expression With Poor Survival in Triple-Negative Breast Cancer Implication for Retinoic Acid Therapy. Am J Pathol. 2011 Mar;178(3):997-1008.
Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB. An exploratory study of composition as a determinant of Epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011 Jan;67(1):93-101.
Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer. Oncologist. 2011;16(1):25-35.
McNeely ML, Peddle CJ, Yurick JL, Dayes IS, Mackey JR. Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer. 2011 Mar 15;117(6):1136-48.
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol. 2011 Apr;22(4):857-62.
Mackey JR. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol. 2011 April:29(12):1504-6.
Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10;29(2):149-56.
Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer. 2010 Nov 15;116(22):5200-6.
Spratlin JL, Mackey JR.  Human equilabrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: towards individualized treatment decisions. Cancers 2010, 2, 2044-2054.
Craik AC, Veldhoen RA, Czernick M, Buckland TW, Kyselytzia K, Ghosh S, Lai R, Damaraju S, Underhill DA, Mackey JR, Goping IS. The BH-3 only Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism. Oncogene. 2010 Sep 30;29(30):5381-91.
Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol. 2010 Jul;6(7):1085-94.
Dolan LB, Gelmon KA, Courneya KS, Mackey JR, Segal RJ, Lane K, Reid RD, McKenzie DC. Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2826-32.
Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur J Histochem. 2010;54(3):e38.
Armanious H, Gelebart P, Mackey J, Ma Y, Lai R. STAT3 upregulates the protein expression and transcriptional activity of b-catenin in breast cancer. Int J Clin Exp Pathol. 2010 Jul 25;3(7):654-64.
Asgarian N, Hu X, Aktary Z, Chapman KA, Lam L, Chibbar R, Mackey J, Greiner R, Pasdar M. Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins. Breast Cancer Res Treat.  2010 Jun;121(2):527-38.
Armanious H, Deschenes J, Gelebart P, Ghosh S, Mackey J, Lai R. Clinical and biological significance of GSK-3beta inactivation in breast cancer-an immunohistochemical study. Hum Pathol. 2010 Dec; 41(12):1657-63.
Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D. Optimizing the management of Her2-positive early breast cancer: the clinical reality. Curr Oncol. 2010 Aug;17(4):20-33.
Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients with Biliary Tract Cancer (BTC). Curr Cancer Drug Targets. 2010 Jan 1;11(1):123-9.
McNeely ML, Campbell K, Ospina M, Rowe BH, Dabbs K, Klassen TP, Mackey J, Courneya K. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev. 2010 Jun 16;6:CD005211.
Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechere L, Reed JC. BCIRG001 Molecular Analysis: Prognostic Factors in Node-positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. Clin Cancer Res. 2010 Aug 1;16(15):3988-97.
Karimi-Busheri F, Rasouli-Nia Aghdass, Mackey JR. Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res. 2010;12(3)R31.
Hack TF, Pickles T, Ruether JD, Weir L, Bultz BD, Mackey J, Degner LF. Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology. 2010 Jun;19(6):606-16.
Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC. Metabolic Modulation of Glioblastoma with Dichloroacetate. Sci Transl Med. 2010 May 12;2(31):31ra34.
Andre F, Broglio K, Pusztai L, Berrada N, Mackey JR, Nabholtz JM, Chan S, Hortobagyi GN. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials. Oncologist. 2010, 15 (5): 476-83.
Germain DR,  Graham K,  Glubrecht DD, Hugh J, Mackey JR, Godbout R. DEAD Box 1: A Novel and Independent Prognostic Marker for Early Recurrence in Breast Cancer. Breast Cancer Res Treat. 2010 May 25.
Prado CMM, Lima ISF, Baracos VE, Bies R, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB. An Exploratory Study of Body Composition as a Determinant of Epirubicin Pharmacokinetics and Toxicity. Cancer Chemother Pharmacology: Volume 67, Issue 1 (2011), Page 93-101. 2010 Mar 5.
Vallance J, Plotnikoff RC, Karvinen KH, Mackey JR, Courneya KS. Understanding physical activity maintenance in breast cancer survivors. Am J Health Behav. 2010 Mar-Apr;34(2):225-36.
Aktary Z, Chapman K, Lam L, Lo A, Ji C, Graham K, Cook L, Li L, Mackey JR, Pasdar M. Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. Oncogene. 2010 Apr 8; 29(14):2118-29.
Damaraju S, Zhang N, Li N, Tao L, Damaraju VL, Dufour J, Santos C, Sun XJ, Mackey J, Wishart DS, Cass CE, Li L. Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell line. Anal Biochem. 2010 Apr 8;29(14):2118-29.
Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010 May;223(2):284-8.
Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol, 2010 Feb 20;28(6);967-76.
Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Deviere J, Van Laethem JL. Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer, 2010 Nov 15:116(22):5200-06.
Damaraju S, Zhang N, Li N, Tao L, Damaraju VL, Dufour J, Santos C, Sun XJ, Mackey J, Wishart DS, Cass CE, Li L. Evidence for Co-purification of Micronuclei in Sucrose Density Gradient Enriched Plasma Membranes from Cell Lines. Anal Biochem. 2010 Jan 1, 396(1)69-75.
Mackey J, Gelmon K, Martin M, McCarthy N, Pinter T, Rupin M, Youssoufian H. TRIO 012: A multicentre, multinational, randomized, double-blind Phase III Study of IMC-1121B Plus Docetaxel versus placebo plus Docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer, 2009 Nov; 9(4): 258-61.
Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE. Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):450-63.
McNeely ML, Campbell KL, Courneya KS, Mackey JR. Effect of acute exercise on upper limb volume in breast cancer survivors: a pilot study. Physiother Can. 2009 Fall;61(4):244-251.
Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B. Beta 1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor -2-Positive Breast Cancer. Cancer Res. 2009 Nov 15;69(22):8620-8.
Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J, Pritchard KI, Rayson D, Verma Sh, Verma Su, Wang B and Chia S. The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers. Current Oncology 16(5):316-325, 2009.
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab Plus Anastrozole Versus Anastrozole alone for the Treatment of Postmenopausal Women with Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study. J Clin Oncol. 2009 Nov 20;27(33):5529-37.
Dent S, Verma Sh., Latreille J, Rayson D, Clemons M, Mackey J, Verma Su., Lemieux  J, Provencher L, Chia S, Wang B, Pritchard K. The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Current Oncology 16(4):25-35, 2009.
Vallance, J.K., Plotnikoff, R.C., Karvinen, K.H., Mackey, J.R., & Courneya, K.S. Understanding physical activity maintenance in breast cancer survivors. American Journal of Health Behavior, 34(2), 225-236, 2009.
Haykowsky MJ, Mackey JR, Thompson RB, Jones LW and Paterson DI. Adjuvant trastuzumab Induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009 Aug 1;15(15):4963-7. Epub 2009 Jul 21.
Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009 Jun;10(6):598-605.
Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K, Laing K, Provencher L, Charbonneau LF. Adjuvant targeted therapy in early breast cancer. Cancer. 2009 Mar 15;115(6):1154-68.
Eastell R, Adams J, Clack G, Howell A, Hannon R, Cuzick J, Mackey J, Beckmann MW, Coleman R. Long-term effects of Anastrozole of bone mineral density: 7-year results from the ATAC Trial. J Clin Oncol, in press, 2009.
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treillieux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast Cancer subtypes and response to docetaxel in node positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8): 1168-76, 2009.
Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Deviere J, Van Laethem JL. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15(9): 2913-9, 2009.
Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic mreast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009 15(8):2920-6.
Sève P, Mackey J, Sawyer M, Lesimple T, de la Fouchardière C, Broussolle C, Dumontet C, Ray-Coquard I.  Impact of  clinical practice guidelines on the management of carcinomas of unknown primary site: a controlled “before-after” study. Bull Cancer 2009, 96(4):E7-17
Friedenreich CM, Gregory J, Kopciuk KA, Mackey JR, Courneya KS. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer, 2009 April 15;124(8): 1954-62.
Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan;136(1):187-95.
Courneya KS, Friedenreich CM, Reid RD, Gelmon K, Mackey JR, Ladha AB, Proulx C, Vallance JK, Segal RJ.  Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy. Breast Cancer Res Treat. 2009 Mar;114(1):179-87.